Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pictilisib + carboplatin + paclitaxel + bevacizumab
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Small Molecules, Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
This combination therapy consists of four distinct agents: **pictilisib**, a pan-phosphatidylinositol 3-kinase (PI3K) inhibitor; **carboplatin**, a platinum-based DNA-damaging chemotherapeutic; **paclitaxel**, a microtubule stabilizer; and **bevacizumab**, a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A) to inhibit angiogenesis. The regimen has been evaluated in phase Ib trials for solid tumors, including locally advanced or metastatic breast cancer and non–small cell lung cancer, aiming to simultaneously block PI3K-mediated growth signaling, induce DNA damage, disrupt microtubules, and inhibit tumor blood vessel formation. Typical administration is intravenous for carboplatin, paclitaxel, and bevacizumab, with oral administration for pictilisib. This combination is investigational and not an established standard of care.
- Other names
- pictilisib + carboplatin + paclitaxel + bevacizumab
02
Targets
DNAPIK3CA (Phosphoinositide 3-kinase alpha)PIK3CB (Phosphatidylinositol 3-kinase beta subunit)PIK3CD (Phosphatidylinositol 3-kinase delta)PI3Kγ (Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform)VEGFA (Vascular endothelial growth factor A)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on pictilisib + carboplatin + paclitaxel + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pictilisib + carboplatin + paclitaxel + bevacizumab.